What is the Medigen Vaccine Biologics Corporation stock price forecast?

Medigen Vaccine Biologics Corporation is currently trading at $45.50. View real-time AI analysis on Alpha Lenz.

What is Medigen Vaccine Biologics Corporation insider trading activity?

View the latest insider trading data for Medigen Vaccine Biologics Corporation on Alpha Lenz.

What is Medigen Vaccine Biologics Corporation's P/E ratio?

View Medigen Vaccine Biologics Corporation's valuation metrics on Alpha Lenz.

Medigen Vaccine Biologics Corporation

TWSE · 6547

NT$45.50+0.10(+0.22%)

Ask about Medigen Vaccine Biologics Corporation's future dividend policy...

Alpha Chat Insight

“Medigen Vaccine Biologics Corporation's ROE is -7.7%. Explore profitability and growth together.”

Ask for details →

Company Overview

Medigen Vaccine Biologics Corporation is a biotechnology company specializing in the research, development, and manufacturing of vaccines and biopharmaceuticals. Founded in 2012 and headquartered in Zhubei City, Taiwan, the company is dedicated to addressing global and regional infectious diseases, operating with certified mass-production capabilities for vaccines and biologics. Its portfolio encompasses vaccines in various stages of development, including candidates targeting COVID-19, enterovirus A71, dengue, respiratory syncytial virus (RSV), and influenza. Medigen's work includes advancing both live attenuated and inactivated viral vaccines and developing products adaptable for diverse delivery containers. Positioned within the healthcare sector, the company plays a significant role in regional public health, particularly highlighted by its rapid response during the COVID-19 pandemic. Through international alliances and a focus on affordable biosimilar drugs, Medigen aims to become a central R&D and manufacturing hub in the Asia-Pacific, supporting global efforts to control and prevent infectious diseases.

Websitehttps://www.medigenvac.com

SectorHealthcare

IndustryBiotechnology

Company Statistics

FY 2025

Profile

N/AMarket Cap

NT$613.17MRevenue

0.00Shares Out

0Employees

Margins

59.47%Gross

-21.38%EBITDA

-43.33%Operating

-45.94%Pre-Tax

-45.94%Net

Valuation

N/AP/E

N/AP/B

N/AEV/Sales

N/AEV/EBITDA

N/AP/FCF

Growth (CAGR)

18.87%Rev 3Yr

121.47%Rev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-6.79%ROA

-7.69%ROE

-6.58%ROIC

Financial Health

NT$592.04MCash & Cash Equivalents

NT$-137.39MNet Debt

13.07%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Medigen Vaccine Biologics Corporation's ROE is -7.7%. Explore profitability and growth together.”

Ask for details →

Frequently Asked Questions

Medigen Vaccine Biologics Corporation (ticker: 6547) is a company listed on TWSE in the Healthcare sector (Biotechnology).

The current price is 45.5 with a P/E ratio of -x and P/B of -x.

ROE is -7.69% and operating margin is -43.33%. Annual revenue is $613M.